CoChat

Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study

Open access
Bhatia, Shailender, Curti, Brendan, Ernstoff, Marc S, Gordon, Michael, Heath, Elisabeth I, Miller, Wilson H, Puzanov, Igor, Quinn, David I, Flaig, Thomas W, VanVeldhuizen, Peter, Byrnes-Blake, Kelly, Freeman, Jeremy A, Bittner, Rachel, Hunder, Naomi, Souza, Sonia, Thompson, John A · 2014 · Journal for ImmunoTherapy of Cancer
Cited by 56

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Despite the positive impact of targeted therapies on metastatic renal cell carcinoma (mRCC), durable responses are infrequent and an unmet need exists for novel therapies with distinct mechanisms of action. We investigated the combination of recombinant Interleukin 21 (IL-21), a cytokine with unique immunostimulatory properties, plus sorafenib, a VEGFR tyrosine kinase inhibitor. METHODS: In this phase 1/2 study, 52 mRCC patients received outpatient treatment with oral sorafenib 400 mg twice daily plus intravenous IL-21 (10-50 mcg/kg) on days 1-5 and 15-19 of each 7-week treatment course. The safety, antitumor activity, pharmacokinetic and pharmacodynamic effects of the combination were evaluated. RESULTS: In phase 1 (n = 19), the maximum tolerated dose for IL-21 with the standard dose of sorafenib was determined to be 30 mcg/kg/day; grade 3 skin rash was the only dose-limiting toxicity. In phase 2, 33 previously-treated patients tolerated the combination therapy well with appropriate dose reductions; toxicities were mostly grade 1 or 2. The objective response rate was 21% and disease control rate was 82%. Two patients have durable responses that are ongoing, despite cessation of both IL-21 and sorafenib, at 41+ and 30+ months, respectively. The median progression-free survival in phase 2 was 5.6 months. The pharmacokinetic and pharmacodynamic properties of IL-21 appeared to be preserved in the presence of sorafenib. CONCLUSION: IL-21 plus sorafenib has antitumor activity and acceptable safety in previously treated mRCC patients. IL-21 may represent a suitable immunotherapy in further exploration of combination strategies in mRCC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00389285.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/2051-1426-2-2

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 56

Metadata

Authors
Bhatia, S., Curti, B., Ernstoff, M. S., Gordon, M., Heath, E. I., Miller, W. H., Puzanov, I., Quinn, D. I., Flaig, T. W., VanVeldhuizen, P., Byrnes-Blake, K., Freeman, J. A., Bittner, R., Hunder, N., Souza, S., & Thompson, J. A.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2014-01-27
Volume
2
Issue
1
Pages
2-2
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2105562405
Cited by
56
References
3
FWCI
4.85
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. https://app.cochat.ai/papers/10.1186/2051-1426-2-2
The paper
Bhatia, S., Curti, B., Ernstoff, M. S., Gordon, M., Heath, E. I., Miller, W. H., Puzanov, I., Quinn, D. I., Flaig, T. W., VanVeldhuizen, P., Byrnes-Blake, K., Freeman, J. A., Bittner, R., Hunder, N., Souza, S., & Thompson, J. A. (2014). Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/2051-1426-2-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.